Skip to main content
. 2016 Sep 19;7(44):71378–71389. doi: 10.18632/oncotarget.12110

Figure 7. Formulated PEITC in pluronic F127 nanoparticles exhibited potent anti-CLL activity in vitro and in vivo.

Figure 7

(A) Formulated PEITC in pluronic F127 nanoparticles and original free PEITC exhibited similar cytotoxicity against CLL cells. Cell viability was analyzed by flow cytometry after double staining with Annexin V-PI. (B) Bar graphs showing quantitative analysis of cell death in mouse leukemia cells treated with 5 μM formulated PEITC and PEITC for 24 h. **p < 0.01. (C) Survival curve (Kaplan-Meier) of control TCL1-Tg:p53−/− mice (untreated, n = 47), and mice treated with formulated PEITC- (n = 16). Median survival time for formulated PEITC treated TCL1-Tg:p53−/− mice was 7.8 months compared to 3.5 months for untreated mice, p < 0.01 between the two groups.